Brief: Arch Biopartners says European Commission designated AB569 as orphan medicinal product in EU
01/06/2016 20:29
June 1 (Reuters) - Arch Biopartners Inc ACH.V :
* European Commission designated AB569 as orphan medicinal
product in European Union for treatment of patients with cystic
fibrosis
Source text for Eikon: ID:nMKWL46zLa
Further company coverage: ACH.V
((Bengaluru Newsroom +1 646 223 8780;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide